Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants
Open Access
- 25 September 2020
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 109 (3) , 658-666
Abstract
“Microdoses” of lysergic acid diethylamide (LSD) are used recreationally to enhance mood and cognition. Increasing interest has also been seen in developing LSD into a medication. Therefore, we performed a pharmacokinetic‐pharmacodynamic study using very low doses of LSD. Single doses of LSD base (5, 10, and 20 µg) and placebo were administered in a double‐blind, randomized, placebo‐controlled crossover study in 23 healthy participants. Test days were separated by at least 5 days. Plasma levels of LSD and subjective effects were assessed up to 6 hours after administration. Pharmacokinetic parameters were determined using compartmental modeling. Concentration‐subjective effect relationships were described using pharmacokinetic‐pharmacodynamic modeling. Mean (95% confidence interval) maximal LSD concentrations were 151 pg/mL (127–181), 279 pg/mL (243–320), and 500 pg/mL (413–607) after 5, 10, and 20 µg LSD administration, respectively. Maximal concentrations were reached after 1.1 hours. The mean elimination half‐life was 2.7 hours (1.5–6.2). The 5 µg dose of LSD elicited no significant acute subjective effects. The 10 µg dose of LSD significantly increased ratings of “under the influence” and “good drug effect” compared with placebo. These effects began an average of 1.1 hours after 10 µg LSD administration, peaked at 2.5 hours, and ended at 5.1 hours. The 20 µg dose of LSD significantly increased ratings of “under the influence,” “good drug effects,” and “bad drug effects.” LSD concentrations dose‐proportionally increased at doses as low as 5–20 µg and decreased with a half‐life of 3 hours. The threshold dose of LSD base for psychotropic effects was 10 µg.Keywords
This publication has 28 references indexed in Scilit:
- A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteersJournal of Psychopharmacology, 2020
- Pharmacokinetics and subjective effects of 1P‐LSD in humans after oral and intravenous administrationDrug Testing and Analysis, 2020
- Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjectsNeuropsychopharmacology, 2019
- Microdosing psychedelics: More questions than answers? An overview and suggestions for future researchJournal of Psychopharmacology, 2019
- Might Microdosing Psychedelics Be Safe and Beneficial? An Initial ExplorationJournal of Psychoactive Drugs, 2019
- Drug liking and wanting, not impulsive action or reflection is increased by 4-fluoroamphetaminePsychopharmacology, 2018
- Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjectsPsychopharmacology, 2017
- Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in HumansInternational Journal of Neuropsychopharmacology, 2015
- Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening DiseasesJournal of Nervous & Mental Disease, 2014
- Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trialsJournal of Psychopharmacology, 2012